Please login to the form below

Not currently logged in
Email:
Password:

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Keytruda combo outshines Opdivo in kidney cancer

Keytruda combo outshines Opdivo in kidney cancer

has landed a blow against rivals BMS and its lead in immunotherapy treatment of renal cell carcinoma (RCC). .

Latest news

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    poor-risk advanced renal cell carcinoma (RCC). ... For now though, BMS is one step ahead. “Currently, less than 50% of patients with metastatic renal cell carcinoma survive beyond two years, and there is almost no complete remission observed,

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    studies of NKTR-214 in front-line and second-/third-line non–small-cell lung cancer (NSCLC) in the second-quarter, and are now working on 20 indications across nine tumour ... and sarcoma, adding to the previously-disclosed studies in melanoma, renal

  • Roche pulls EU Tecentriq/Avastin filing in kidney cancer Roche pulls EU Tecentriq/Avastin filing in kidney cancer

    Roche has opted to withdraw its filing in Europe for a dual regimen for renal cell carcinoma based on checkpoint inhibitor Tecentriq and Avastin, on the grounds that the data supporting ... line use of the pair in non-small cell lung cancer (NSCLC) based

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    Company faces pressure from competitors in renal cell carcinoma. Bristol-Myers Squibb chief executive Giovani Caforio barely mentioned the company’s finances on its third-quarter results call before launching into ... that BMS’ was the first company

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... Pfizer when it presents the JAVELIN Renal 101 study of its

More from news
Approximately 7 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in

  • Charting a course for expansion Charting a course for expansion

    Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Deal Watch December 2015 Deal Watch December 2015

    510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics